JPH0352480B2 - - Google Patents
Info
- Publication number
- JPH0352480B2 JPH0352480B2 JP58061102A JP6110283A JPH0352480B2 JP H0352480 B2 JPH0352480 B2 JP H0352480B2 JP 58061102 A JP58061102 A JP 58061102A JP 6110283 A JP6110283 A JP 6110283A JP H0352480 B2 JPH0352480 B2 JP H0352480B2
- Authority
- JP
- Japan
- Prior art keywords
- tgf
- urine
- subjected
- manufactured
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000694 effects Effects 0.000 claims description 23
- 210000002700 urine Anatomy 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 18
- 238000010828 elution Methods 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 12
- 238000002523 gelfiltration Methods 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000004255 ion exchange chromatography Methods 0.000 claims description 9
- 230000007935 neutral effect Effects 0.000 claims description 9
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 9
- 239000000385 dialysis solution Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 125000001165 hydrophobic group Chemical group 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 45
- 108010009583 Transforming Growth Factors Proteins 0.000 description 45
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000000502 dialysis Methods 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- 238000010998 test method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000001332 colony forming effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- -1 carbon chain-modified silica gel Chemical class 0.000 description 7
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001155 isoelectric focusing Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002156 adsorbate Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- YCRPAFAWTMUXCW-UHFFFAOYSA-N 2,2,2-trichloroacetic acid;hydrate Chemical compound O.OC(=O)C(Cl)(Cl)Cl YCRPAFAWTMUXCW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58061102A JPS59186994A (ja) | 1983-04-06 | 1983-04-06 | 細胞形質転換増殖因子の製造法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58061102A JPS59186994A (ja) | 1983-04-06 | 1983-04-06 | 細胞形質転換増殖因子の製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59186994A JPS59186994A (ja) | 1984-10-23 |
| JPH0352480B2 true JPH0352480B2 (enrdf_load_stackoverflow) | 1991-08-12 |
Family
ID=13161382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58061102A Granted JPS59186994A (ja) | 1983-04-06 | 1983-04-06 | 細胞形質転換増殖因子の製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59186994A (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686455B1 (en) * | 1984-07-05 | 2004-02-03 | Genentech, Inc. | Tumor necrosis factor |
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US5047510A (en) * | 1988-01-07 | 1991-09-10 | Ostuka Pharmaceutical Co. Ltd. | Method of purification of transforming growth factor-beta |
-
1983
- 1983-04-06 JP JP58061102A patent/JPS59186994A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59186994A (ja) | 1984-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1431691A3 (ru) | Способ получени гликопротеина | |
| US4002602A (en) | Ubiquitous immunopoietic polypeptide (UBIP) and methods | |
| JPS62501701A (ja) | 均質なエリトロポエチン | |
| GB2058081A (en) | Method of producing a substance for curing human granulocytopoenia | |
| WO2006111060A1 (fr) | Procede permettant d’isoler et de purifier un polypeptide immuno-modulant a partir du placenta de vache | |
| JPS6322526A (ja) | 肝細胞増殖因子 | |
| EP0090892B1 (en) | Process for the purification of physiologically active substance having antitumour activity | |
| SU1375116A3 (ru) | Способ получени фактора УШ:С свертывани крови | |
| Burgos | Angiogenic factor from human term placenta. Purification and partial characterization | |
| EP0132125B2 (en) | A protein having antitumor activity | |
| EP0212501A2 (en) | Therapeutic agent for treating hematopoietic diseases | |
| JPH0352480B2 (enrdf_load_stackoverflow) | ||
| US4148886A (en) | Polypeptide possessing thymic activity | |
| CN113789319B (zh) | 从蝇蛆中分离蛆激酶的方法及应用 | |
| JPH0296598A (ja) | リンフォカイン活性化キラー細胞誘導抑制因子ｌａｋｓｆ，その製造法およびそれを有効成分とする免疫抑制剤 | |
| ES2395937T3 (es) | Proceso para producir lactoperoxidasa | |
| US4610815A (en) | Process for producing and obtaining anaphylatoxin- and cocytotaxin-containing leucotaxine preparations and of anaphylatoxin and cocytotaxin proteins in molecularly homogeneous, biologically active form | |
| Argiles et al. | Dialysis-associated amyloidosis in a patient on long-term post-dilutional hemofiltration | |
| JPS61218523A (ja) | 腫瘍細胞増殖抑制剤および殺腫瘍細胞因子の製造法 | |
| JPH02502640A (ja) | Ｇｍ‐ｃｓｆの精製 | |
| JPS6043333B2 (ja) | 抗炎症活性物質の製法 | |
| JPH0413696A (ja) | 新規生理活性物質 | |
| US5023320A (en) | Process for the purification of physiologically active substance having antitumor activity | |
| NO850152L (no) | Fremgangsmaate ved fremstilling av human, endogen cancerregulerende faktor. | |
| JPS60226816A (ja) | 抗腫瘍活性をもつヒト由来蛋白質 |